Alnylam Pharmaceuticals (ALNY) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) recently:

• 8/9/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/7/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at HC Wainwright from $500.00 to $570.00. They now have a “buy” rating on the stock.
• 8/6/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $348.00 to $475.00. They now have an “overweight” rating on the stock.
• 8/4/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating.
• 8/4/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings, Inc. from a “market perform” rating to an “outperform” rating. They now have a $490.00 price target on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Scotiabank from $342.00 to $450.00. They now have a “sector outperform” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Barclays PLC from $329.00 to $460.00. They now have an “overweight” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Piper Sandler from $304.00 to $449.00. They now have an “overweight” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $333.00 to $395.00. They now have an “equal weight” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $312.00 to $405.00. They now have an “equal weight” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at UBS Group AG from $403.00 to $550.00. They now have a “buy” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $390.00 to $415.00. They now have a “buy” rating on the stock.
• 8/1/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Chardan Capital from $325.00 to $400.00. They now have a “buy” rating on the stock.
• 7/31/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $377.00 to $478.00. They now have a “buy” rating on the stock.
• 7/30/2025 – Alnylam Pharmaceuticals is now covered by analysts at Raymond James Financial, Inc.. They set an “outperform” rating and a $370.00 price target on the stock.
• 7/21/2025 – Alnylam Pharmaceuticals is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $385.00 price target on the stock.
• 7/16/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $338.00 to $348.00. They now have an “overweight” rating on the stock.
• 7/11/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $364.00 to $404.00. They now have a “buy” rating on the stock.
• 7/11/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $336.00 to $359.00. They now have a “buy” rating on the stock.
• 7/7/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $328.00 to $384.00. They now have a “buy” rating on the stock.
• 7/5/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 6/30/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $287.00 to $333.00. They now have an “equal weight” rating on the stock.
• 6/26/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $320.00 to $377.00. They now have a “buy” rating on the stock.
• 6/24/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $300.00 to $360.00. They now have an “outperform” rating on the stock.

Alnylam Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ ALNY opened at $432.52 on Thursday. The company has a market capitalization of $56.69 billion, a price-to-earnings ratio of -175.11 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The business has a 50-day moving average of $339.44 and a two-hundred day moving average of $287.99. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $445.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.13) EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares of the company’s stock, valued at $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Jump Financial LLC increased its position in shares of Alnylam Pharmaceuticals by 9.3% during the second quarter. Jump Financial LLC now owns 17,177 shares of the biopharmaceutical company’s stock worth $5,601,000 after purchasing an additional 1,460 shares in the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $241,000. First Trust Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 39.5% during the second quarter. First Trust Advisors LP now owns 251,817 shares of the biopharmaceutical company’s stock worth $82,115,000 after purchasing an additional 71,357 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 8.2% during the second quarter. Kennedy Capital Management LLC now owns 1,668 shares of the biopharmaceutical company’s stock worth $544,000 after purchasing an additional 127 shares in the last quarter. Finally, 1832 Asset Management L.P. increased its position in shares of Alnylam Pharmaceuticals by 55.1% during the second quarter. 1832 Asset Management L.P. now owns 223,345 shares of the biopharmaceutical company’s stock worth $72,831,000 after purchasing an additional 79,300 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.